The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
control	O
value	O
.	O

The	O
risk	O
of	O
developing	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	O
cancer	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
,	I-Disease
ureter	I-Disease
or	I-Disease
bladder	I-Disease
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	B-Chemical
or	O
paracetamol	B-Chemical
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O

His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	B-Disease
of	O
the	O
fingers	O
and	O
foot	O
.	O

The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis	O
;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	B-Chemical
B6	I-Chemical
.	O

In	O
patient	O
1	O
,	O
plasma	O
levels	O
of	O
deoxycorticosterone	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
deoxycortisol	I-Chemical
were	O
elevated	O
.	O

Transient	O
cranial	B-Disease
nerve	I-Disease
dysfunction	I-Disease
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	B-Chemical
.	O

RESULTS	O
:	O
The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	O
IgA	B-Disease
nephropathy	I-Disease
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=	O
2	O
)	O
,	O
minimal	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	O
-	O
type	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
11	O
)	O
.	O

Sirolimus	B-Chemical
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	O
allograft	O
nephropathy	B-Disease
.	O

Almost	O
certainly	O
,	O
nicotine	B-Chemical
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events	O
,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	B-Chemical
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	O
or	O
the	O
effects	O
of	O
carbon	B-Chemical
monoxide	I-Chemical
.	O

Severe	O
hematologic	O
toxicity	B-Disease
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

Preliminary	O
studies	O
suggest	O
that	O
statins	B-Chemical
could	O
interfere	O
with	O
the	O
risk	O
of	O
recurrence	O
after	O
electrical	O
cardioversion	O
.	O

Nephrotoxicity	B-Disease
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	B-Chemical
and	O
urea	B-Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

All	O
concentrations	O
of	O
nicotine	B-Chemical
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	B-Chemical
lethality	O
was	O
0	O
.	O
75	O
%	O
.	O

Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	B-Disease
and	I-Disease
kidney	I-Disease
toxicity	I-Disease
,	O
with	O
greater	O
severity	O
in	O
the	O
orally	O
-	O
treated	O
animal	O
.	O

However	O
,	O
compression	B-Disease
neuropathy	I-Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	B-Chemical
-	O
induced	O
myopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
in	O
wild	O
-	O
type	O
Wistar	O
rats	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
improvement	O
in	O
the	O
dyskinesia	B-Disease
score	O
without	O
increase	O
of	O
parkinsonian	B-Disease
motor	B-Disease
disability	I-Disease
.	O

Rabbit	B-Disease
syndrome	I-Disease
(	O
RS	B-Disease
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

However	O
,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage	O
,	O
duration	O
of	O
phenytoin	B-Chemical
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters	O
.	O

A	O
case	O
of	O
metabolic	B-Disease
acidosis	I-Disease
,	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
and	I-Disease
hepatic	I-Disease
failure	I-Disease
following	O
paracetamol	B-Chemical
ingestion	O
is	O
presented	O
.	O

Eighty	O
-	O
nine	O
new	O
referral	O
hypertensive	B-Disease
out	O
-	O
patients	O
and	O
46	O
new	O
referral	O
non	O
-	O
hypertensive	B-Disease
chronically	O
physically	O
ill	O
out	O
-	O
patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year	O
.	O

In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8	O
,	O
000	O
mefloquine	B-Chemical
users	O
suffers	O
from	O
such	O
reactions	O
.	O

Hydrogen	B-Chemical
cyanamide	I-Chemical
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees	O
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	B-Disease
aneurysms	I-Disease
and	O
no	O
history	O
of	O
cocaine	B-Disease
abuse	I-Disease
.	O

The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	B-Disease
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade	O
.	O

Cimetidine	B-Chemical
clearance	O
decreased	O
with	O
age	O
.	O

A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	B-Chemical
via	O
a	O
patient	O
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O

This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	B-Chemical
in	O
healthy	O
,	O
older	O
(	O
>	O
65	O
years	O
)	O
,	O
and	O
middle	O
-	O
aged	O
(	O
35	O
to	O
55	O
years	O
)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	B-Disease
.	O

Because	O
sirolimus	B-Chemical
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	O
inhibitors	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
nephrotoxic	B-Disease
drug	O
'	O
.	O

